A planned merger between US biotech Sesen Bio (Nasdaq: SESN) and privately-held firm Carisma Therapeutics has run into headwinds.
Sesen stock fell by a third after the merger was announced in mid-September, before recovering somewhat, as shareholders pored over the implications for the company.
News that the merger agreement had been amended, announced at the end of 2022, lifted the price of Sesen shares, although they have still not recovered to their pre-September levels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze